Can-Fite BioPharma (TASE:CFBI;OTC:CANFY) has moved to China production of the active pharmaceuticals ingredients (API) of CF101 and CF102. The ingredients are to be up-scaled and manufactured by Chemspec, a leading Chinese
CRO. This will support the on-going advanced stage clinical trials conducted by the
to supply API to its current and future strategic partners. . CF101 is currently developed for the treatment of autoimmune inflammatory
diseases including rheumatoid arthritis (Phase 2b) and psoriasis (Phase 2/3). CF101 is
also developed for ophthalmic indications including dry eye syndrome (Phase 3),
glaucoma (Phase 2) and Uveitis by OphthaliX (OTC:OPLI), a subsidiary of Can-Fite.
CF102 is a small orally bioavailable drug which bind with high affinity and selectivity to
the A3 adenosine receptor. The latter is highly expressed in tumor cells whereas low
expression is found in normal cells. This differential effect accounts for the excellent
safety profile of the drug. The drug induces a robust anti-tumor effect via de-regulation of
the Wnt signaling pathway, resulting in apoptosis of liver cancer cells.
About Can-Fite BioPharma Ltd.